drugset
drugset / Trial / NCT02844439

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439 ↗

Phase 2 Completed 40 enrolled Kadmon Corporation, LLC
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

Timeline

Start
2016-06
Primary completion
2020-04-30
Completion
2020-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tesevatinib Small molecule 300 mg Oral

Indications

brain neoplasm glioblastoma